Latest Regulatory Progress News

Page 4 of 58
EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.
Victor Sage
Victor Sage
15 Sept 2026
Equus Energy has completed Pre-FEED on its large North West Shelf gas project and signed a conditional 10-year gas sales agreement with Alcoa. But the annual report also shows a $25 million loss, a $12 million rehabilitation provision and substantial funding and permitting hurdles before development can begin.
Maxwell Dee
Maxwell Dee
8 Sept 2026
OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.
Ada Torres
Ada Torres
7 Sept 2026
Central Asia Metals shareholders have greenlit the allotment of new shares to fund their acquisition of Cygnus Metals, marking a pivotal step in the takeover process. Bell Potter joins Morgans to help Cygnus shareholders navigate CREST accounts for trading post-scheme.
Maxwell Dee
Maxwell Dee
7 Sept 2026
Po Valley Energy secures regulatory green light for Selva Malvezzi drilling program as August gas sales hit a three-year revenue high, backed by a new 12-month gas supply contract with Hera Trading.
Maxwell Dee
Maxwell Dee
4 Sept 2026
Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
Ada Torres
Ada Torres
2 Sept 2026
Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.
Ada Torres
Ada Torres
1 Sept 2026
Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.
Ada Torres
Ada Torres
31 Aug 2026
Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.
Victor Sage
Victor Sage
31 Aug 2026
Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.
Victor Sage
Victor Sage
31 Aug 2026
Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.
Ada Torres
Ada Torres
31 Aug 2026
Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.
Ada Torres
Ada Torres
28 Aug 2026

Browse the archive

Full archive